研究者詳細 - 齋藤　豪

卵巣漿液性腺癌stage3再発例の検討

鈴木孝浩, 田中綾一, 森下美幸, 水戸菜々子, 松浦基樹, 藤本尚, 梅村康太, 伊東英樹, 斉藤豪

日本婦人科腫瘍学会雑誌 25 ( 3 ) 254 2007年06月

hCG低下中に腹腔内出血を認め緊急手術となった子宮外妊娠の1例

森下美幸, 鈴木孝浩, 松浦基樹, 両坂美和, 井上行信, 斉藤豪

北海道産科婦人科学会会誌 51 ( 1 ) 36 - 37 2007年06月

多嚢胞性卵巣症候群とインスリン抵抗性関連遺伝子の多型

馬場剛, 遠藤俊明, 本間寛之, 北島義盛, 松浦基樹, 南妃奈, 西川聡, 石岡伸一, 林卓宏, 金谷美加, 真名瀬賢吾, 佐田文宏, 岸玲子, 山田秀人, 水上尚典, 神谷博文, 森若治, 齋藤豪

日本内分泌学会雑誌 82 ( 4 ) 864 2007年03月

難治性絨毛癌に対しFA療法が有効であった1例

松浦基樹, 鈴木孝浩, 谷垣衣理, 森下美幸, 藤本尚, 伊東英樹, 斎藤豪

産科と婦人科 74 ( 3 ) 357 - 361 2007年03月

多嚢胞性卵巣症候群とインスリン抵抗性関連遺伝子の多型

馬場剛, 遠藤俊明, 本間寛之, 北島義盛, 林卓宏, 金谷美加, 真名瀬賢吾, 佐田文宏, 山田秀人, 水上尚典, 神谷博文, 斎藤豪

日本産科婦人科学会雑誌 ( (公社)日本産科婦人科学会 ) 59 ( 2 ) 569 - 569 2007年02月

P1-115 バイスタンダー効果を応用した子宮体癌に対する遺伝子治療の研究(Group10 子宮体部腫瘍3,一般演題,第59回日本産科婦人科学会学術講演会)

鈴木孝浩, 森下美幸, 松浦基樹, 田中綾一, 藤本尚, 水戸菜々子, 斎藤豪

日本産科婦人科學會雜誌 ( 日本産科婦人科学会 ) 59 ( 2 ) 2007年

P2-29 子宮頸癌に対する術前Weekly TJ及び放射線併用療法Phase1, 2study(Group104 子宮頸部腫瘍8,一般演題,第59回日本産科婦人科学会学術講演会)

水戸菜々子, 鈴木孝浩, 森下美幸, 田中綾一, 松浦基樹, 斎藤豪

日本産科婦人科學會雜誌 ( 日本産科婦人科学会 ) 59 ( 2 ) 2007年

バイスタンダー効果を応用した遺伝子治療の研究

鈴木孝浩, 森下美幸, 松浦基樹, 藤本尚, 斉藤豪

日本癌治療学会誌 41 ( 2 ) 298 2006年09月

P2-57 進行子宮体癌に対する放射線・化学療法併用の効果について(Group 120 子宮体部腫瘍IX,一般演題,講演要旨,第58回日本産科婦人科学会学術講演会)

松浦基樹, 鈴木孝浩, 森下美幸, 井上行信, 伊東英樹, 斎藤豪

日本産科婦人科學會雜誌 ( 日本産科婦人科学会 ) 58 ( 2 ) 2006年

子宮頸部腺癌の取り扱い子宮頸部腺癌の化学療法術前Neoadjuvant化学療法(NAC療法)としてのPaclitaxel+CBDCA併用療法(TJ療法)の有用性について

石岡伸一, 寒河江悟, 杉村政樹, 江坂嘉昭, 斉藤豪

日本婦人科腫瘍学会雑誌 ( (公社)日本婦人科腫瘍学会 ) 23 ( 3 ) 422 - 426 2005年06月

1989年以降に治療を行ったBulky腫瘍を有する臨床進行期IbからIIIbの子宮頸部腺癌で,術前paclitaxel+CBDCA併用療法(TJ療法)を施行した5例について,従来のPAM療法を施行した28例との間で臨床的比較検討を行い,術前化学療法(NAC療法)としてのTJ療法の有用性を検討した.PAM療法群はCDDP 70mg/m2,AclacinomycinA 15mg/m2,MitomycinC 10mg/m2を4週ごとに2〜3コース,TJ療法群はPTX 175mg/m2,CBDCAをACU6にて4週ごとに2〜3コース施行後に,根治手術を施行した.TJ療法後,5例中4例,80%で腫瘍サイズの減少(縮小率61〜89%)を認めた.また,画像診断上のTJ療法後の骨盤リンパ節および子宮傍組織浸潤の所見と実際の摘出物の所見はほぼ相関し,TJ療法のNAC療法としての良好な一次治療効果を示したものと考えられた.副作用の発現はGrade3の好中球減少の発現がやや多いものの,G-CSFの投与にてコントロール可能であった

子宮内膜癌症例における子宮頸部細胞診所見(子宮体部5, 第46回日本臨床細胞学会総会(春期大会))

鈴木孝浩, 伊東英樹, 田中綾一, 藤本尚, 野田雅也, 永井美帆, 斉藤豪

日本臨床細胞学会雑誌 ( 特定非営利活動法人日本臨床細胞学会 ) 44 ( 1 ) 2005年03月

Hypermethylation in promoter region of retinoic acid receptor-beta gene and immunohistochemical findings on retinoic acid receptors in carcinogenesis of endometrium

R Li, T Saito, R Tanaka, S Satohisa, K Adachi, M Horie, Y Akashi, R Kudo

CANCER LETTERS ( ELSEVIER IRELAND LTD ) 219 ( 1 ) 33 - 40 2005年02月

In the present study, we analyzed the immunohistochemical findings for the RA receptor (RAR), retinoic X receptor (RXR) and hypermethylation of promoter-region CpG island methylation of RAR-beta2. Immunohistochemistry indicated that though RXR-alpha and -gamma were present in endometrial hyperplasia and cancer, other retinoid receptors were only weakly detected. The hypermethylation of RAR-beta2 was found in 75.0% of endometrial hyperplasia samples and 92.2% of carcinomas. No normal endometria had methylation. This evidence may point to one of the reasons why endometrial hyperplasia acquires high proliferative capacity without differentiation, and the hypermethylation of RAR-beta2 may occur in the early stage of endometrial carcinogenesis. (C) 2004 Elsevier Ireland Ltd. All rights reserved.

Nerve-preserving techniques for radical hysterectomy

E Ito, T Saito

EJSO ( ELSEVIER SCI LTD ) 30 ( 10 ) 1137 - 1140 2004年12月

Aims. Postoperative bladder dysfunction of varying severity is common after radical hysterectomy due to damage to the pelvic autonomic nerves during surgical resection. Pelvic autonomic nerve damage occurs at two main sites: the fibrous tissue at the lateral aspect of the uterosacral. ligament (FLUSL) and the posterior layer of the vesicouterine ligament (PLVUL). In this article, we classify the main sites of pelvic autonomic nerve damage based on previous reports and our own experience, outline the problems with current nerve-preserving techniques, and describe an improved nerve-preserving technique that we have developed. Results. We present urodynamic data for 25 patients who underwent radical hysterectomy using the nerve-preserving technique we described previously and preliminary results for four patients treated by the latest technique. To avoid pelvic autonomic nerve damage, injury to the FLUSL and PLVUL should be minimized. For the FLUSL, we have obtained relatively good Madder function with the cardinal ligament pull-through technique. However, a new method is needed for management of the PLVUL, since the only way to minimize nerve damage at this site currently is to limit the extent of PLVUL resection. (C) 2004 Elsevier Ltd. All rights reserved.

Identification of SCN3B as a novel p53-inducible proapoptotic gene

K Adachi, M Toyota, Y Sasaki, T Yamashita, S Ishida, M Ohe-Toyota, R Maruyama, Y Hinoda, T Saito, K Imai, R Kudo, T Tokino

ONCOGENE ( NATURE PUBLISHING GROUP ) 23 ( 47 ) 7791 - 7798 2004年10月

Tumor suppressor p53 is a transcription factor that induces growth arrest and/or apoptosis in response to cellular stress. To identify novel p53-inducible genes, we compared the expression of genes in normal mouse embryo fibroblasts (MEFs) to p53-null cells by cDNA representational difference analysis. We report here that expression of endogenous sodium channel subunit beta 3 (SCN3B) is upregulated in mouse embryonic fibroblasts by DNA damage in a p53-dependent manner. In addition, we found that SCN3B levels are upregulated in human cancer cell lines by DNA damaging agents, as well as by overexpression of p53, but not significantly by p63 or p73. Furthermore, we identified two putative p53-binding sites upstream of the first exon (RE1) and in the third intron (RE2). The p53 protein can directly interact with the putative p53-binding sites in vivo, as assessed by chromatin immunoprecipitation. A reporter gene assay revealed that these two p53-binding sites are functional response elements. The SCN3B protein appears to be localized to the endoplasmic reticulum (ER). Introduction of the SCN3B gene into T98G and Saos2 cells potently suppressed colony formation. Furthermore, we found that adenovirus-mediated transfer of SCN3B induced apoptosis when combined with anticancer agents. The results presented here suggest that SCN3B mediates a p53-dependent apoptotic pathway and may be a candidate for gene therapy combined with anticancer drugs.

Cytology of vaginal and uterine sarcomas

E Ito, T Saito, T Suzuki, M Fujii, R Kudo

ACTA CYTOLOGICA ( SCI PRINTERS & PUBL INC ) 48 ( 5 ) 601 - 607 2004年09月

OBJECTIVE: To retrospectively review, based on cytologic and histopathologic findings, the diagnoses of 13 patients with uterine sarcoma and 1 with vaginal sacoma. STUDY DESIGN: There were 8 cases of uterine carcinosarcoma (CS), 2 of leiomyosarcoma, 2 of endometrical stromal sarcoma (ESS), 1 of endocervical stromal sarcoma (ECSS) and 1 of malignant fibrous histiocytoma (MFH) of the vagina. The presence of sarcomatous components was retrospectively investigated by microscopic observation of preoperative specimens from the endocervical canal and endometrial cells. Characteristic features of sarcomatous cells were then investigated by cytodiagnostic micrometry of malignant cells. RESULTS: Of the 14 patients, 1 with low grade ESS and 1 with homologous CS were diagnosed as negative for sarcomatous components. One case of high grade ESS had been overlooked, as were 4 cases of CS. Thus, 7 cases (50%) were diagnosed as positive for sarcomatous cells by preoperative cytologic observation. Based. on these findings, 12 of the 14 cases (85.7%) were positive for sarcomatous elements on retrospective reexamination of the specimens. CONCLUSION: Careful attention should be paid to small sarcomatous cells since cases of ESS or ECSS with such cells show morphologic characteristics similar to those of stromatous cells. Furthermore, careful microscopic observation of an entire specimen is required to avoid misdiagnosis as carcinoma since it is easy to overlook sarcomatous elements in smears with carcinosarcoma if there are only a few sarcomatous cells.

Overexpressed progesterone receptor form B inhibit invasive activity suppressing matrix metalloproteinases in endometrial carcinoma cells

T Saito, H Mizumoto, R Tanaka, S Satohisa, K Adachi, M Horie, R Kudo

CANCER LETTERS ( ELSEVIER SCI IRELAND LTD ) 209 ( 2 ) 237 - 243 2004年06月

In this study, we focused on the influence of progesterone and its receptor in invasion and MMPs on endometrial carcinoma cells. The growth of lshikawa cells, to which an progesterone receptor form B (PR-B) expressing vector was transfected, was inhibited by progesterone as was the inhibition of the expression of cyclin D1. By invasion assay, in conditions with progesterone, the invasiveness of Ishikawa cells was inhibited as well as the expression of (metalloproteinase) MMP-1, -2, -7 and -9 and Ets-1 decreased. These results suggest that activation of PR-B by progesterone results in tumor suppression by inhibiting cell growth and invasiveness via suppression of the expression of MMPs. (C) 2004 Elsevier Ltd. All rights reserved.

【腟式手術の現状と今後の課題】腟式子宮全摘出術(TVH)の現状と今後の課題

石岡伸一, 寒河江悟, 寺澤勝彦, 杉村政樹, 江坂嘉昭, 斉藤豪, 伊東英樹, 工藤隆一

産婦人科手術 ( (株)メジカルビュー社 ) ( 15 ) 47 - 53 2004年06月

Neoadjuvant chemotherapy with cisplatin, aclacinomycin A, and mitomycin C for cervical adenocarcinoma - a preliminary study

T Saito, M Takehara, R Lee, T Fujimoto, M Nishimura, R Tanaka, E Ito, K Adachi, R Kudo

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER ( BLACKWELL PUBLISHING INC ) 14 ( 3 ) 483 - 490 2004年05月

Between 1989 and 2002, 28 patients with locally advanced cervical adenocarcinoma (bulky IB-IIIB) were recruited for a pilot study aimed at evaluation of the effectiveness of neoadjuvant chemotherapy with cisplatin, aclacinomycin-A, and mitomycin-C (PAM), followed by radical surgery. This regimen was administrated intra-arterially or intravenously. In addition to patients treated with PAM, we retrospectively analyzed the prognoses of 26 patients in stage I and II, who had been treated between 1975 and 1981 with radical surgery with/without radiation therapy. Twenty-eight patients received PAM therapy as neoadjuvant chemotherapy, and 75.0% of the 16 intra-arterially infused patients showed a response, as did 66.7% of the 12 intravenously infused patients. There was a significant difference in the 5-year prognosis of stage II (PAM group, 72.9%; without-PAM group, 36.4%). The results suggest that, as the free space in the parametrium is widened by neoadjuvant chemotherapy with PAM, it is possible that the tumor could be completely resected by radical hysterectomy. Thus, neoadjuvant chemotherapy with PAM is expected to improve the survival rate of patients with advanced cervical adenocarcinoma by the preliminary study. However, the survival rates of stage II with lymph node metastasis in the without-PAM group seem low, and we must also consider that the various technologies to evaluate and treat the cervical adenocarcinomas, e.g. computed tomography, magnetic resonance imaging, and surgical equipments, had improved during 1989-2002 than was the scenario during 1975-1981, and these improvements contributed to better prognosis. A prospective-randomized study is needed to assess the value of this approach compared with standard management.

Expression of uteroglobin in normal and carcinogenic endometrium and influence of hormone replacement therapy

R Tanaka, T Saito, N Shijubo, M Takehara, G Yamada, Kawabata, I, Y Itoh, R Kudo

INTERNATIONAL JOURNAL OF CANCER ( WILEY-LISS ) 109 ( 1 ) 43 - 48 2004年03月

Uteroglobin, first reported in 1968 as a steroid secreted in rabbit uterine fluid during early pregnancy, is a progesterone-regulated and progesterone-binding protein. There is evidence that indicates that uteroglobin is inversely correlated to neoplastic growth but its role to endometrial carcinogenesis is not known. Therefore we analyzed the expression of uteroglobin in 13 normal endometrium, 19 hyperplasia and 21 endometrial carcinoma samples and the relation to estrogen receptor-alpha (ER-alpha) and progesterone receptor (PR) by immunohistochemistry and Western blotting. We also analyzed the expression of uteroglobin in 15 menopausal women who received hormone replacement therapy (HRT). The expression of uteroglobin was higher during the secretory phase than in the proliferative phase; however, it was detected in endometrial hyperplasia as weakly as in the proliferative phase and decreased according to the loss of differentiation in endometrial carcinoma. The results were basically in accord with those for PR; however, the expression of uteroglobin was weak, though PR was most detected in endometrial hyperplasia. In menopausal endometrium,the group treated with estrogen plus progesterone exhibited higher expression of uteroglobin than the group treated only with estrogen. The evidence suggests that uteroglobin expression is regulated by progesterone in the normal endometrium but that the regulation by PR is lost in endometrial hyperplasia and carcinoma according to acquirement of tumorigenesis and that estrogen plus progesterone therapy reduces the risk for endometrial carcinoma by restoring uteroglobin. (C) 2003 Wiley-Liss, Inc.